Valuing Patents in Pharmaceuticals and Biotechnology

Roberto Moro-Visconti ()
Additional contact information
Roberto Moro-Visconti: Catholic University of the Sacred Heart

Chapter Chapter 11 in Patent Valuation, 2025, pp 391-430 from Springer

Abstract: Abstract Examining patents in the pharmaceutical and biotech industries is vital in encouraging innovation, protecting investments, and driving advances in healthcare and biotechnology. This chapter explores patent evaluation through the lens of emerging modalities such as personalized medicine, telemedicine, gene editing, digital therapeutics, bioprinting, and RNA technologies. The chapter emphasizes the critical need for flexible approaches to valuation, strategic management of IP, and novel research directions needed to traverse this rapidly evolving environment and its associated challenges.

Keywords: Gene editing (CRISPR) R&D; Digital therapeutics; RNA technologies; FDA approval (search for similar items in EconPapers)
Date: 2025
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-3-031-88443-6_11

Ordering information: This item can be ordered from
http://www.springer.com/9783031884436

DOI: 10.1007/978-3-031-88443-6_11

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().